vs
Side-by-side financial comparison of FORWARD AIR CORP (FWRD) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $631.2M, roughly 1.7× FORWARD AIR CORP). Hologic runs the higher net margin — 17.1% vs -4.5%, a 21.6% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -0.3%). Over the past eight quarters, FORWARD AIR CORP's revenue compounded faster (7.9% CAGR vs 1.5%).
Forward Air Corp is a leading North American asset-light logistics and transportation provider. It offers core services including expedited less-than-truckload freight delivery, final-mile logistics, intermodal transport, warehousing, and supply chain solutions, serving key sectors such as e-commerce, retail, manufacturing, and automotive across the U.S., Canada, and Mexico.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
FWRD vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $631.2M | $1.0B |
| Net Profit | $-28.3M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | -0.5% | 22.6% |
| Net Margin | -4.5% | 17.1% |
| Revenue YoY | -0.3% | 2.5% |
| Net Profit YoY | 22.2% | -10.9% |
| EPS (diluted) | $-0.90 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $631.2M | $1.0B | ||
| Q3 25 | $631.8M | $1.0B | ||
| Q2 25 | $618.8M | $1.0B | ||
| Q1 25 | $613.3M | $1.0B | ||
| Q4 24 | $632.8M | $1.0B | ||
| Q3 24 | $655.9M | $988.0M | ||
| Q2 24 | $643.7M | $1.0B | ||
| Q1 24 | $541.8M | $1.0B |
| Q4 25 | $-28.3M | $179.1M | ||
| Q3 25 | $-16.3M | $187.2M | ||
| Q2 25 | $-12.6M | $194.9M | ||
| Q1 25 | $-50.6M | $-17.4M | ||
| Q4 24 | $-36.4M | $201.0M | ||
| Q3 24 | $-73.4M | $178.6M | ||
| Q2 24 | $-645.4M | $194.5M | ||
| Q1 24 | $-61.7M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | -0.5% | 22.6% | ||
| Q3 25 | 2.4% | 22.6% | ||
| Q2 25 | 3.2% | 24.9% | ||
| Q1 25 | 0.8% | -0.7% | ||
| Q4 24 | 12.0% | 22.5% | ||
| Q3 24 | 3.5% | 23.3% | ||
| Q2 24 | -170.2% | 24.1% | ||
| Q1 24 | -12.1% | 20.7% |
| Q4 25 | -4.5% | 17.1% | ||
| Q3 25 | -2.6% | 17.8% | ||
| Q2 25 | -2.0% | 19.0% | ||
| Q1 25 | -8.3% | -1.7% | ||
| Q4 24 | -5.8% | 19.7% | ||
| Q3 24 | -11.2% | 18.1% | ||
| Q2 24 | -100.3% | 19.2% | ||
| Q1 24 | -11.4% | 16.7% |
| Q4 25 | $-0.90 | $0.79 | ||
| Q3 25 | $-0.52 | $0.84 | ||
| Q2 25 | $-0.41 | $0.86 | ||
| Q1 25 | $-1.68 | $-0.08 | ||
| Q4 24 | $-1.69 | $0.87 | ||
| Q3 24 | $-2.66 | $0.75 | ||
| Q2 24 | $-23.47 | $0.82 | ||
| Q1 24 | $-2.81 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $106.0M | $2.4B |
| Total DebtLower is stronger | $1.7B | $2.5B |
| Stockholders' EquityBook value | $113.3M | $5.2B |
| Total Assets | $2.7B | $9.2B |
| Debt / EquityLower = less leverage | 14.89× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $106.0M | $2.4B | ||
| Q3 25 | $140.4M | $2.2B | ||
| Q2 25 | $95.1M | $1.9B | ||
| Q1 25 | $116.3M | $1.6B | ||
| Q4 24 | $104.9M | $2.0B | ||
| Q3 24 | $136.6M | $2.3B | ||
| Q2 24 | $84.9M | $2.4B | ||
| Q1 24 | $152.0M | $2.2B |
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | $1.7B | $2.6B |
| Q4 25 | $113.3M | $5.2B | ||
| Q3 25 | $139.8M | $5.0B | ||
| Q2 25 | $151.8M | $4.8B | ||
| Q1 25 | $154.6M | $4.6B | ||
| Q4 24 | $201.7M | $4.8B | ||
| Q3 24 | $226.1M | $5.1B | ||
| Q2 24 | $283.8M | $5.0B | ||
| Q1 24 | $926.1M | $4.8B |
| Q4 25 | $2.7B | $9.2B | ||
| Q3 25 | $2.8B | $9.0B | ||
| Q2 25 | $2.8B | $8.8B | ||
| Q1 25 | $2.8B | $8.5B | ||
| Q4 24 | $2.8B | $8.7B | ||
| Q3 24 | $3.1B | $9.2B | ||
| Q2 24 | $3.1B | $8.9B | ||
| Q1 24 | $4.0B | $8.7B |
| Q4 25 | 14.89× | 0.48× | ||
| Q3 25 | 12.05× | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | 1.81× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | 1.3% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $229.9M | ||
| Q3 25 | $52.7M | $355.1M | ||
| Q2 25 | — | $343.3M | ||
| Q1 25 | $27.6M | $169.4M | ||
| Q4 24 | $-23.2M | $189.3M | ||
| Q3 24 | $51.2M | $367.0M | ||
| Q2 24 | $-45.2M | $405.8M | ||
| Q1 24 | $-51.7M | $292.4M |
| Q4 25 | — | $215.2M | ||
| Q3 25 | $48.6M | $341.4M | ||
| Q2 25 | — | $330.5M | ||
| Q1 25 | $15.7M | $153.9M | ||
| Q4 24 | $-30.5M | $172.5M | ||
| Q3 24 | $40.7M | $350.6M | ||
| Q2 24 | $-59.6M | $385.3M | ||
| Q1 24 | $-56.7M | $279.6M |
| Q4 25 | — | 20.5% | ||
| Q3 25 | 7.7% | 32.5% | ||
| Q2 25 | — | 32.3% | ||
| Q1 25 | 2.6% | 15.3% | ||
| Q4 24 | -4.8% | 16.9% | ||
| Q3 24 | 6.2% | 35.5% | ||
| Q2 24 | -9.3% | 38.1% | ||
| Q1 24 | -10.5% | 27.5% |
| Q4 25 | 1.3% | 1.4% | ||
| Q3 25 | 0.7% | 1.3% | ||
| Q2 25 | 0.8% | 1.3% | ||
| Q1 25 | 1.9% | 1.5% | ||
| Q4 24 | 1.1% | 1.6% | ||
| Q3 24 | 1.6% | 1.7% | ||
| Q2 24 | 2.2% | 2.0% | ||
| Q1 24 | 0.9% | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 1.90× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | — | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FWRD
| Omni Logistics Segment | $359.8M | 57% |
| Network | $183.9M | 29% |
| Intermodal Segment | $50.2M | 8% |
| Truckload | $41.6M | 7% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
